Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers-Reference-Cited by-同舟云学术

Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers

Published:2014-01-29 Issue:3 Volume:6 Page:88-100
ISSN:1758-8359
Container-title:Therapeutic Advances in Medical Oncology
language:en
Short-container-title:Ther Adv Med Oncol

Author:

Davis S. Lindsey¹,Eckhardt S. Gail¹,Tentler John J.¹,Diamond Jennifer R.²

Affiliation:

1. Department of Medical Oncology, University of Colorado Cancer Center, Aurora, CO, USA

2. Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Mailstop 8117, 12801 East 17th Avenue, Aurora, CO 80045, USA

Abstract

Triple-negative breast cancer (TNBC) represents a challenge clinically due to a lack of response to hormonal and HER2-targeted agents coupled with an aggressive disease course. As the biology of this breast cancer subtype is better understood, it is clear that TNBC is a heterogeneous disease and one targeted therapy is unlikely to be active in all patients. Biomarkers predictive of response to treatment are thus of great importance in TNBC. This review outlines studies evaluating biomarkers predictive of response to neoadjuvant chemotherapy and to targeted therapies in the advanced setting. The development of validated biomarkers in conjunction with novel targeted therapies represents an opportunity to improve patient outcomes in TNBC.

Publisher

SAGE Publications

Subject

Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1758834013519843

Reference60 articles.

1. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

2. Basal-like breast carcinomas: clinical outcome and response to chemotherapy

3. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype

4. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes

5. Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineered immunologic niche monitors checkpoint blockade response and probes mechanisms of resistance;ImmunoMedicine;2024-06

2. Novel Strategies Using Sagacious Targeting for Site-Specific Drug Delivery in Breast Cancer Treatment: Clinical Potential and Applications;Critical Reviews™ in Therapeutic Drug Carrier Systems;2024

3. What Is Bioanalytical Chemistry? Scientific Opportunities with Immediate Impact;Tools and Trends in Bioanalytical Chemistry;2021-11-26

4. Breast Cancer Heterogeneity;Diagnostics;2021-08-27

5. Inhibition of retinoic acid receptor α phosphorylation represses the progression of triple-negative breast cancer via transactivating miR-3074-5p to target DHRS3;Journal of Experimental & Clinical Cancer Research;2021-04-26